Personalized Glucose Management System with Adaptive Canagliflozin Dosing

A next-generation system for personalized glycemic management, integrating wearable glucose sensors, AI-driven dosing algorithms, and bioresponsive Canagliflozin formulations for real-time release profiling and adaptive dosing.

The original patent relates to a pharmaceutical composition comprising Canagliflozin, which, while effective, has limitations in terms of dosing and glucose level monitoring. The new inventive concept addresses these limitations by envisioning a system that combines wearable glucose sensors, AI-driven algorithms, and adaptive Canagliflozin dosing to provide personalized glycemic management.

The system consists of a wearable glucose sensor that continuously monitors glucose levels, an AI-driven dosing algorithm that processes the data and generates a customized dosing regimen, and a Canagliflozin-containing oral dosage form adapted for real-time release profiling. The bioresponsive polymer in the formulation modulates the release of Canagliflozin in response to changes in blood glucose levels. The system also includes a smart tablet with an ingestible sensor, a communication module, and a data analytics platform for tracking patient adherence and treatment outcomes. The closed-loop system enables real-time feedback control, ensuring optimal glucose levels and minimizing side effects.

The new claims introduce a paradigm shift in glucose management by integrating wearable sensors, AI-driven algorithms, and bioresponsive formulations, which is not obvious from the original patent. The inventive concept's novelty lies in its ability to provide personalized, adaptive, and real-time glycemic management, making it a significant improvement over existing technologies.

Alternative embodiments of the inventive concept could include different types of wearable sensors, such as implantable or non-invasive sensors, or various AI-driven algorithms tailored to specific patient populations. Variations could also include different bioresponsive polymers or formulations adapted for specific glucose level ranges or patient needs.

The personalized glucose management system has significant commercial potential in the diabetes management market, with potential applications in pharmaceuticals, medical devices, and digital health. The system could be marketed to patients with type 1 and type 2 diabetes, as well as to healthcare providers and payers seeking to improve treatment outcomes and reduce healthcare costs.